Celeste Decker

1.1k total citations
21 papers, 685 citations indexed

About

Celeste Decker is a scholar working on Physiology, Epidemiology and Rheumatology. According to data from OpenAlex, Celeste Decker has authored 21 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Physiology, 10 papers in Epidemiology and 4 papers in Rheumatology. Recurrent topics in Celeste Decker's work include Lysosomal Storage Disorders Research (17 papers), Trypanosoma species research and implications (10 papers) and Child Nutrition and Feeding Issues (4 papers). Celeste Decker is often cited by papers focused on Lysosomal Storage Disorders Research (17 papers), Trypanosoma species research and implications (10 papers) and Child Nutrition and Feeding Issues (4 papers). Celeste Decker collaborates with scholars based in United States, United Kingdom and Italy. Celeste Decker's co-authors include Paul Harmatz, Barbara K. Burton, Nathalie Guffon, Roberto Giugliani, Christian J. Hendriksz, Murat Emre, Simon Jones, John J. Mitchell, Robert D. Steiner and Paige Kaplan and has published in prestigious journals such as SHILAP Revista de lepidopterología, PEDIATRICS and Journal of Immunological Methods.

In The Last Decade

Celeste Decker

21 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Celeste Decker United States 17 550 258 236 98 83 21 685
Norberto Guelbert Argentina 16 514 0.9× 216 0.8× 232 1.0× 68 0.7× 27 0.3× 39 651
Karen Tylee United Kingdom 16 580 1.1× 259 1.0× 158 0.7× 40 0.4× 80 1.0× 45 704
Shuan-Pei Lin Taiwan 19 371 0.7× 210 0.8× 206 0.9× 46 0.5× 28 0.3× 39 793
Müge Güçsavaş‐Çalıkoğlu United States 7 797 1.4× 415 1.6× 277 1.2× 136 1.4× 75 0.9× 10 1.1k
Alexander Broomfield United Kingdom 14 358 0.7× 124 0.5× 137 0.6× 56 0.6× 40 0.5× 54 613
Esmée Oussoren Netherlands 15 383 0.7× 169 0.7× 166 0.7× 37 0.4× 33 0.4× 32 768
Agnieszka Jurecka Poland 21 649 1.2× 446 1.7× 293 1.2× 73 0.7× 59 0.7× 63 1.2k
Laila Arash Germany 7 565 1.0× 284 1.1× 174 0.7× 54 0.6× 81 1.0× 8 629
Maira Graeff Burin Brazil 21 918 1.7× 388 1.5× 206 0.9× 49 0.5× 96 1.2× 65 1.1k
Elke Miebach Germany 13 989 1.8× 521 2.0× 291 1.2× 84 0.9× 121 1.5× 15 1.1k

Countries citing papers authored by Celeste Decker

Since Specialization
Citations

This map shows the geographic impact of Celeste Decker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Celeste Decker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Celeste Decker more than expected).

Fields of papers citing papers by Celeste Decker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Celeste Decker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Celeste Decker. The network helps show where Celeste Decker may publish in the future.

Co-authorship network of co-authors of Celeste Decker

This figure shows the co-authorship network connecting the top 25 collaborators of Celeste Decker. A scholar is included among the top collaborators of Celeste Decker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Celeste Decker. Celeste Decker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burton, Barbara K., Nicola Longo, Jerry Vockley, et al.. (2020). Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up. Molecular Genetics and Metabolism. 130(4). 239–246. 19 indexed citations
2.
Zori, Roberto T., Janet A. Thomas, Natasha Shur, et al.. (2018). Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria. Molecular Genetics and Metabolism. 125(3). 217–227. 25 indexed citations
3.
Longo, Nicola, Roberto T. Zori, Melissa Wasserstein, et al.. (2018). Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study. Orphanet Journal of Rare Diseases. 13(1). 108–108. 25 indexed citations
4.
5.
Hendriksz, Christian J., Rossella Parini, Moeenaldeen AlSayed, et al.. (2017). Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study. Molecular Genetics and Metabolism. 123(2). 127–134. 22 indexed citations
6.
Hendriksz, Christian J., Rossella Parini, Moeenaldeen AlSayed, et al.. (2017). Elosulfase alfa treatment and changes in physical functioning and disability in Morquio syndrome type A. Molecular Genetics and Metabolism. 120(1-2). S65–S65. 1 indexed citations
7.
Melton, Andrew C., Troy Tompkins, Brian Long, et al.. (2016). Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome. Journal of Immunological Methods. 440. 41–51. 14 indexed citations
8.
Long, Brian, Troy Tompkins, Celeste Decker, et al.. (2016). Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study. Clinical Therapeutics. 39(1). 118–129.e3. 26 indexed citations
9.
Harmatz, Paul, Eugen Mengel, Tarekegn Geberhiwot, et al.. (2016). Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open‐label, phase 2 study. American Journal of Medical Genetics Part A. 173(2). 375–383. 22 indexed citations
10.
Hendriksz, Christian J., Kenneth I. Berger, Rossella Parini, et al.. (2016). Impact of long‐term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome. Journal of Inherited Metabolic Disease. 39(6). 839–847. 22 indexed citations
11.
Harmatz, Paul, Eugen Mengel, Roberto Giugliani, et al.. (2014). Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome. Molecular Genetics and Metabolism. 114(2). 186–194. 31 indexed citations
12.
Harmatz, Paul, Eugen Mengel, Roberto Giugliani, et al.. (2013). The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Molecular Genetics and Metabolism. 109(1). 54–61. 110 indexed citations
13.
Harmatz, Paul, Paula Garcia, Nathalie Guffon, et al.. (2013). Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI. Journal of Inherited Metabolic Disease. 37(2). 277–287. 29 indexed citations
14.
15.
Lorget, Florence, Sung Wook Lee, Laurie Tsuruda, et al.. (2012). BMN 110 (Recombinant Human GALNS), an Investigational Enzyme Replacement Therapy for Mucopolysaccharidosis Type IVA (MPS IVA Or Morquio Syndrome), Promotes Type II Collagen Synthesis in MPS IVA Patients. Molecular Genetics and Metabolism. 105(2). S44–S44. 3 indexed citations
16.
Burnett, Vicki L., et al.. (2011). Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers. Orphanet Journal of Rare Diseases. 6(1). 84–84. 21 indexed citations
17.
Decker, Celeste, Zi‐Fan Yu, Roberto Giugliani, et al.. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Pediatric Rehabilitation Medicine. 3(2). 89–100. 52 indexed citations
18.
Harmatz, Paul, Roberto Giugliani, Ida Vanessa Döederlein Schwartz, et al.. (2008). Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Molecular Genetics and Metabolism. 94(4). 469–475. 159 indexed citations
19.
20.
Emre, Murat & Celeste Decker. (1992). Effects of Cigarette Smoking on Motor Functions in Patients With Multiple Sclerosis. Archives of Neurology. 49(12). 1243–1247. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Norberto Guelbert Breakdown of academic impact, for papers by Karen Tylee Breakdown of academic impact, for papers by Shuan-Pei Lin Breakdown of academic impact, for papers by Müge Güçsavaş‐Çalıkoğlu Breakdown of academic impact, for papers by Alexander Broomfield Breakdown of academic impact, for papers by Esmée Oussoren Breakdown of academic impact, for papers by Agnieszka Jurecka Breakdown of academic impact, for papers by Laila Arash Breakdown of academic impact, for papers by Maira Graeff Burin Breakdown of academic impact, for papers by Elke Miebach
Rankless by CCL
2026